Pfizer, Metsera, ACIP, vaccines: Readout E-newsletter
Need to keep on prime of the science and politics driving biotech at present? Enroll to get our biotech e-newsletter in your inbox.
Morning. Right now, we examine a giant acquisition fueled by weight problems, docs shifting their views on biopharma advertising, see a uncommon illness drug win approval after an extended stretch of uncertainty, and extra.
Pfizer to amass Metsera, developer of weight problems medicine
Pfizer is paying $47.50 a share in money for Metsera, a 43% premium on the startup’s closing worth on Friday that provides the deal an enterprise worth of $4.9 billion. The pact additionally features a contingent worth proper price as much as $22.50 a share based mostly on potential scientific and regulatory milestones for Metsera’s medicines.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
